Cerevel Therapeutics’ highly selective dopamine D1/D5 agonist showed significant reductions in UPDRS-III scores for those with early-stage Parkinson disease and is planned to enter phase 3 in 2020.
from Front page feed https://ift.tt/331Dvzv
from Front page feed https://ift.tt/331Dvzv
Comments
Post a Comment